Anke Biotech announced that a total of 20 products from the company and its subsidiaries were included in the “National Essential Drug Catalogue”. Three new products were selected, namely the company's product trastuzumab for injection, the wholly-owned subsidiary Anke Hengyi product, propofol fumarate tenofovir tablets, and the holding subsidiary Anke Yu Liangqing's product heat-cleansing and detoxifying oral solution. The total sales revenue of the above three new varieties in 2025 was 259 million yuan, accounting for 9.80% of the company's 2025 revenue. The announcement stated that the inclusion of this product in the essential drug catalogue will not have a significant impact on the company's performance in the short term, and will help expand the product market and increase sales volume in the long term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.